Research programme: neutropenia therapy - LTT Bio-Pharma
Alternative Names: SRGLatest Information Update: 07 Oct 2015
At a glance
- Originator LTT Bio-Pharma
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neutropenia
Most Recent Events
- 10 May 2010 Early research in Neutropenia in Japan (unspecified route)